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Objectives.Toinvestigatetheprognosticimpactofthenumberofdissectedlymphnodes(LNs)ingastriccanceraftercurativedistal
gastrectomy. Methods. The survival of 634 patients who underwent curative distal gastrectomy from 1995 to 2004 was retrieved.
Long-term surgical outcomes and associations between the number of dissected LNsand the 5-year survival ratewere investigated.
Results. The number of dissected LNs was one of the most important prognostic indicators. Among patients with comparable T
category,thelargerthenumberofdissectedLNswas,thebetterthesurvivalwouldbe(P<0.05).Thelinearregressionshowedthat
a signiﬁcant survival improvement based on increasing retrieved LNs for stage II, III and IV (P<0.05). A cut-point analysis yields
the greatest variance of survival rate diﬀerence at the levels of 15 LNs (stage I), 25 LNs (stage II) and 30 LNs (stage III). Conclusion.
The number of dissected LNs is an independent prognostic factor for gastric cancer. To improve the long-term survival of patients
with gastric cancer, removing at least 15 LNs for stage I, 25 LNs for stage II, and 30 LNs for stage III patients during curative distal
gastrectomy is recommended.
1.Introduction
Although gastric cancer is a declining incidence, its mortality
remains high [1]. Complete resection is currently the only
treatment that can lead to cure for gastric cancer. Recently,
the surgical procedures and the extent of lymphadenectomy
for gastric cancer receive more recognition with the ongoing
in-depth researches [2]. Comparing with total gastrectomy,
distal gastrectomy raises the lower postoperative morbidity
and mortality rates and improves postoperative life quality
and nutrition condition. It is regarded as one of the most
important operative procedures for gastric cancer [2–4]. The
goal of surgery for gastric cancer is R0 resection, but the
optimal extent of lymphadenectomy remains controversial
[5–7]. In the 1997 UICC TNM classiﬁcation (5th edition),
it was recommended that 15 or more lymph nodes should be
examined for accurate staging of gastric cancer [8]. However,
there are fewer studies on how many nodes should be
removed and examined during performing a radical distal
gastrectomy for diﬀerent stages [9, 10]. Therefore, the aim of
this retrospective study is to evaluate the long-term eﬀect of
the number of dissected LNs on the prognosis after curative
distal gastrectomy in patients with gastric cancer.
2.MaterialsandMethods
2.1. Materials. 1289 patients diagnosed as primary gastric
cancer were treated with curative resection (R0) at the
Department of Gastric Surgery, Fujian Medical University
Union Hospital, Fuzhou, China, between January, 1995
and November, 2004. All the operations were undertaken
according to the Japanese Classiﬁcation of Gastric Car-
cinoma (JCGC) [11]. Most of the early gastric cancer
received D1 + α/β LN dissection, while more advanced
gastric cancer received a D2 LN dissection (a few of patients
with advanced gastric cancer who received a D1 + α/β
LN dissection were estimated as early gastric cancer or
without LN metastasis before or during the operation).
There were 709 patients who underwent distal gastrectomy,
and 75 patients were excluded from the study for T4b lesions2 Gastroenterology Research and Practice
(T4blesionswerenotincludedtoavoiddataheterogeneity,as
resections in these cases were expected to be more extensive,
and the likelihood for positive margins was judged to be
higher). Finally, 634 patients were enrolled in this study. The
curative surgery was deﬁned as follows: (1) complete tumor
removal; (2) no macroscopic residual tumor; (3) no invasion
of carcinoma cells in the margin; (4) no evidence of distant
metastasis. Most of nodal materials were separately dissected
from the en bloc specimen at the end of the procedure
by the surgeons, and the remainder nodes were identiﬁed
and retrieved by specialized pathologists from formalin-
ﬁxedsurgicalspecimenswithoutusinganyspeciﬁctechnique
to increase nodal retrieval rate. Paraﬃn-embedded nodes
were stained with haematoxylin and eosin and examined
microscopically for metastases by specialized pathologists.
Staging was done according to the 7th edition of the UICC
TNM classiﬁcation [12]. Patients were stratiﬁed into seven
groups based on the number of total LNs removed as
follows: 0∼9 LNs (32 cases), 10∼14 LNs (75 cases), 15∼
19 LNs (111 cases), 20∼24 LNs (161 cases), 25∼29 LNs
(118 cases), 30∼34 LNs (78 cases), and ≥35 LNs (59 cases).
Patients with advance gastric cancer received ﬂuorouracil-
based postoperative adjuvant chemotherapy, and there was
no patient who underwent preoperative chemotherapy. The
followup was carried out by trained investigators through
mailings, telephone calls, visiting patients, or recording
the patients’ consultations at the outpatient service. Most
patient routine followup consisted of physical examination,
laboratory tests (including AFP, CA19-9, and CEA levels),
chest radiography, and abdominopelvic ultrasonography or
computed tomography (CT). At the early stage (pT1),
patients were followed up every 6 months during the ﬁrst
2 years, and then every year beyond the third year; at more
advanced stages (pT2 or greater), follow-up was every 3
months during the ﬁrst year, every 6 months, or yearly
b e y o n dt h es e c o n dy e a r ,f o rat o t a lo f5y e a r s .E n d o s c o p y
was performed every 6 months or every year. All surviving
patients were followed up for more than ﬁve years. The
survival time was the time from the surgical intervention
until the last contact, the date of death, or the date that
the survival information was collected. The median follow
up for the entire cohort was 62.0 months (range, 1∼172
months). The followup rate was 93.2%, with 591 cases
involved.
2.2. Statistical Analysis. The statistical analysis has been
performed using the Statistical Package for Social Science
(SPSS) 16.0. Pearson’s correlation coeﬃcient (r)w a su s e df o r
studying the relationship between the number of metastatic
lymph nodes and the number of dissected lymph nodes;
actuarial survival rate was determined via the Kaplan-
Meier method, with univariate comparisons between groups
through the log-rank test. Cox proportional hazard model
was used for multivariate analyse, with a backward elim-
ination model for all covariates. Linear projection model
was applied to analysis the impact of the number of nodes
removed in increments of 10 on absolute 5-year survival.
Signiﬁcance of diﬀerences was assumed at P values less than
0.05 for all analyses.
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Figure 1: Cumulative survival curves for patients undergoing
curativedistalgastrectomyaccordingtothe7theditionoftheUICC
TNM classiﬁcation. There was signiﬁcant diﬀerence between the
subgroups (P<0.05).
3. Results
3.1. Clinicopathological Characteristics of Patients. Clinico-
pathological features of patients are summarized in Table 1.
There were 467 male and 167 female patients whose ages
ranged from 22 to 87 years (56.1 ± 12.1 years). The
tumor diameter was 4.3 ± 1.7cm. Patients were divided
according to the primary site of gastric cancer: 521 lower-
third (L) tumors; 42 lower- and middle-third (LM) tumors;
71 middle-third (M) tumors. According to the Japanese
Classiﬁcation of Gastric Carcinoma [11], there were 140
diﬀerentiated and 494 undiﬀerentiated cases. Based on the
UICC TNM classiﬁcation (7th edition) [12], there were 118
stage pT1, 106 stage pT2, 68 stage pT3, and 342 stage pT4a
tumors. A total of 439 patients (69.2%) had LN metastasis.
The incidence of LN metastasis is 18.1% pN1, 18.5% pN2,
and 32.6% pN3. There were 133 (21.0%) patients with
stage I, 165 (26.0%) stage II, and 336 (53.0%) stage III,
according to the TNM classiﬁcation [12]. There were no
patients with early gastric cancer who received postoperative
chemotherapy, and in all 516 patients with advanced gastric
cancer, 382 cases received postoperative chemotherapy, and
134 patients did not receive postoperative chemotherapy.
3.2. Long-Term Surgical Outcomes. The ﬁve-year overall
survival rate of the entire cohort was 57.6% in this study.
Survival rate at 5 years was 85.0%, 66.0%, and 42.5% for
stages I, II, and III disease, respectively (P<0.05; Figure 1).
3.3. Analysis Based on Lymph Node Metastasis and Retrieved
Nodes. Overall, 69.2% of patients (439/634) had LN metas-
tasis. The median of total LN number was 23 (range, 5–61;Gastroenterology Research and Practice 3
Table 1: Clinical characteristics of the 634 patients.
Characteristics Patients (n = 634)
Gender
Male 467 (73.6)
Female 167 (26.4)
Age (years) 56.1 ± 12.1 (range, 22∼87)
Tumor diameter (cm) 4.3 ± 1.7 (range, 0.5∼15)
Tumor location
Lower 521 (80.8)
Middle 71 (11.2)
Lower and middle 42 (8.0)
Digestive tract construction
Billroth I 469 (74.0)
Billroth II 148 (22.3)
Roux-en-Y 17 (3.7)
Pathology
Diﬀerentiated 140 (22.1)
Undiﬀerentiated 494 (77.9)
Depth of invasion
pT1 118 (18.6)
pT2 106 (16.7)
pT3 68 (10.7)
pT4a 342 (54.0)
pN category
pN0 195 (30.8)
pN1 115 (18.1)
pN2 117 (18.5)
pN3 207 (32.6)
Number of resected LNs
0∼9 LNs 32 (5.0)
10∼14 LNs 75 (11.8)
15∼19 LNs 111 (17.5)
20∼24 LNs 161 (25.4)
25∼29 LNs 118 (18.6)
30∼34 LNs 78 (12.3)
≥35 LNs 59 (9.4)
TNM stage
I 133 (21.0)
II 165 (26.0)
III 336 (53.0)
mean 23.1 ± 8.6) per patient, and the median of positive
LNs was 6 (range, 1–46) per patient. There was a signiﬁcant
correlation between the number of metastatic LNs and
retrieved nodes according to the Pearson’s correlation test
(r = 0.252, P<0.001; Figure 2).
3.4. Univariate and Multivariate Survival Analysis. The clini-
copathologicalvariablestestedintheunivariateanalysiswere
shown in Table 2. The factors inﬂuencing the 5-year survival
rate were tumor diameter (P = 0.036), pathological types
(P = 0.003), depth of invasion (P<0.001), pN category
(P<0.001), and number of dissected LNs (P<0.001).
Table 2: Univariate analysis of variables for patients with curative
distal gastrectomy.
Characteristics N
5-year
survival
(%)
χ2 P
Gender <0.001 0.991
Male 467 58.1
Female 167 56.3
Age (years) 0.641 0.423
<60 370 58.9
≥60 264 56.0
Tumor diameter (cm) 4.409 0.036
≤4 343 61.0
>4 291 53.6
Tumor location 5.693 0.058
Lower 521 57.7
Middle 71 63.7
Lower and middle 42 45.4
Digestive tract construction 5.508 0.064
Billroth I 469 60.7
Billroth II 148 48.5
Roux-en-Y 17 51.0
Pathology 9.135 0.003
Diﬀerentiated 140 68.1
Undiﬀerentiated 494 54.6
Depth of invasion 65.354 0.000
pT1 118 90.6
pT2 106 67.2
pT3 68 60.1
pT4a 342 42.9
pN category 116.863 0.000
pN0 195 83.3
pN1 115 63.6
pN2 117 44.5
pN3 207 31.2
Number of resected LNs 65.288 0.000
0∼9 LNs 32 30.9
10∼14 LNs 75 37.2
15∼19 LNs 111 51.6
20∼24 LNs 161 59.7
25∼29 LNs 118 62.0
30∼34 LNs 78 69.6
≥35 LNs 59 77.7
Adjuvant chemotherapy∗ 1.829 0.117
Yes 382 51.0
No 134 47.8
The covariates gender (P = 0.991), age (P = 0.423), tumor
location (P = 0.058), adjuvant chemotherapy (P = 0.117),
and digestive tract construction (P = 0.064) each had
no signiﬁcant inﬂuence on the survival. Multiple survival4 Gastroenterology Research and Practice
Table 3: Multiple stepwise regression analysis with the Cox proportional hazards model.
Characteristics β SE Wald P RR 95% CI
Tumor diameter −0.042 0.133 0.121 0.689 0.940 0.754–1.317
Pathology −0.012 0.154 0.006 0.933 0.987 0.725–1.315
Depth of invasion 22.738 0.000
pT2 versus pT1 0.684 0.258 8.754 0.009 2.015 1.126–3.570
pT3 versus pT1 0.953 0.250 15.547 0.000 2.943 1.681–4.524
pT4a versus pT1 1.253 0.244 21.636 0.000 3.043 1.981–5.158
pN category t 119.502 0.000
pN1 versus pN0 0.513 0.156 12.244 0.000 2.022 1.401–2.873
pN2 versus pN0 1.364 0.186 48.598 0.000 4.302 3.423–5.966
pN3 versus pN0 2.196 0.237 89.746 0.000 10.379 6.587–18.846
Number of resected LNs −0.425 0.041 106.996 0.000 0.625 0.588–0.736
β:C o e ﬃcient of regression.
Table 4: Five-year overall survival by stage subgroups and total number of resected LNs.
Subgroup N
Number of resected LNs [n,O S( % ) ]
P
0∼91 0 ∼14 15∼19 20∼24 25∼29 30∼34 ≥35
Depth of invasion
pT1 118 6 (62.5) 15
(80.0)
27
(88.9)
29
(93.1)
18
(88.9)
12
(91.7)
11
(100.0) 0.025
pT2 106 7 (28.6) 11
(27.3)
18
(66.7)
28
(75.0)
26
(73.1)
10
(90.0) 8 (87.5) 0.000
pT3 68 3 (33.3) 5 (40.0) 13
(53.8)
15
(60.0) 9 (66.7) 10
(70.0) 11 (72.7) 0.005
pT4a 342 16
(20.2)
44
(23.9)
53
(31.5)
89
(44.4)
65
(50.7)
46
(55.1) 29 (69.0) 0.000
NA: Not applicable; OS: Overall 5-year survival rate.
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Figure 2: Pearson’s correlation tests. Signiﬁcant correlation bet-
ween the number of lymph node metastases and retrieved lymph
nodes (r = 0.252, P<0.001).
analysis was calculated by the Cox’s proportional hazard
regression model. The prognostic factors considered on
univariate analysis were analyzed ﬁrst by the stepwise regres-
sion, including tumor diameter, pathology types, depth of
invasion, pN category, and the number of dissected LNs. As
a result, there were three independent, statistically signiﬁcant
prognostic parameters: depth of invasion (P<0.001), pN
category (P<0.001), and the number of dissected LNs
(P<0.001). The 95% conﬁdence intervals were listed in
Table 3.
3.5. Impact of Total LN Counts on Five-Year Survival by Stage
Subgroup. The overall survival results by stage subgroup and
number of LNs examined were depicted in Table 4.A m o n g
patients with comparable T category, the overall survival rate
was signiﬁcantly diﬀerent and always in favor of the higher
LNcount.Forexample,forthepT1subgroup,5-yearsurvival
rate increased from 62.5% (0 to 9 LNs examined) to 100%
(>35 LNs examined). A similar trend was encountered for
the other subgroups.
3.6. Projected Numeric LN Impact on Overall Survival. Based
on the statistical linearity regression, the impact of the
number of dissected LNs on overall survival was calculated.
The hypothetical baseline 5-year survival with an assumed
zero LN examined was 43.5% for stage I, 13.6% for stage II,Gastroenterology Research and Practice 5
Table 5: Projected numeric total LNs impact on 5-year overall survival.
Stage subgroup Patients (n) β
Baseline projected 5-year
survival (0 LN
examined), %
For every 10 extra LNs
examined, survival
improved by (%)
P value
I 133 0.846 43.5 13.9 0.061
II 165 0.923 13.6 18.7 0.025
III 336 0.964 2.0 15.5 0.003
Total 634 0.952 20.4 13.1 0.001
β:C o e ﬃcient of regression.
Table 6: Pairwise comparisons of overall survival of patients with diﬀerent number of dissected LNs after surgery by Kaplan-Meier method.
Stage Removed LNs
P value
0∼91 0 ∼14 15∼19 20∼24 25∼29 30∼34 ≥35
I
0∼9 — 0.004 0.000 0.000 0.000 0.000 0.000
10∼14 0.004 — 0.046 0.003 0.035 0.040 0.012
15∼19 0.000 0.046 — 0.121 0.375 0.268 0.116
20∼24 0.000 0.003 0.121 — 0.702 0.631 0.540
25∼29 0.000 0.035 0.375 0.702 — 0.387 0.351
30∼34 0.000 0.040 0.268 0.631 0.387 — 1.0
≥35 0.000 0.012 0.116 0.540 0.351 1.0 —
II
0∼9 — 0.889 0.132 0.001 0.000 0.000 0.000
10∼14 0.889 — 0.124 0.000 0.000 0.000 0.000
15∼19 0.132 0.124 — 0.009 0.000 0.000 0.000
20∼24 0.001 0.000 0.009 — 0.044 0.145 0.028
25∼29 0.000 0.000 0.000 0.044 — 0.899 0.963
30∼34 0.000 0.000 0.000 0.145 0.899 — 0.751
≥35 0.000 0.000 0.000 0.028 0.963 0.751 —
III
0∼9 — 0.131 0.107 0.010 0.000 0.000 0.000
10∼14 0.131 — 0.758 0.212 0.033 0.012 0.000
15∼19 0.107 0.758 — 0.087 0.011 0.000 0.000
20∼24 0.010 0.212 0.087 — 0.136 0.026 0.001
25∼29 0.000 0.033 0.011 0.136 — 0.042 0.030
30∼34 0.000 0.012 0.000 0.026 0.042 — 0.198
≥35 0.000 0.000 0.000 0.001 0.030 0.198 —
2.0% for stage III, and 20.4% for the entire cohort. For every
10 extra LNs added to the total LN count, the calculated
overall survival rate increased by 13.9% (stage I), 18.7%
(stage II), 15.5% (stage III), and 13.1% (the entire cohort).
In this setting, the regression model showed a statistically
signiﬁcant survival improvement based on increasing total
LN counts for patients with stages II, III, and the entire
cohort (P<0.05; Table 5).
3.7. Cut-Point Analysis of Survival. A cut-point analysis was
performed to identify the numeric LN value that determines
the obvious actuarial survival diﬀerence between subgroups.
Univariate survival results by stage subgroup and total LN
counts are depicted in Table 6. For the stage I subgroup,
it was found that there were signiﬁcant survival diﬀerences
among the patients with 0∼9L N s ,1 0 ∼14 LNs, and 15∼19
LNs (P<0.05). However, there were not survival diﬀerences
among patients with 15∼19 LNs, 20∼24 LNs, 25∼29 LNs,
30∼34 LNs, and ≥35 LNs with univariate analysis. So we
are convinced that the cutoﬀ level was 15 LNs. In the stage
II subgroup, the survival among patients with 0∼9L N s ,
10∼14 LNs, 15∼19 LNs, 20∼24 LNs, and 25∼29 LNs was
signiﬁcantly diﬀerent (P<0.05). On the contrary, there were
not survival diﬀerences among patients with 25∼29 LNs,
30∼34 LNs, and ≥35 LNs examined. And we suspected that
the cutoﬀ level was 25 LNs for stage II. For the patients with
stage III disease, there were remarkable survival diﬀerences
among patients with 0∼9L N s ,1 0 ∼14 LNs, 15∼19 LNs, 20∼
24 LNs, 25∼29 LNs, and 30∼34 LNs (P<0.05). However,
there were no survival diﬀerences between patients with 30∼
34 LNs and ≥35 LNs. So the cutoﬀ level was regarded as
30 LNs. Thus, it was that the cut-point analysis yields the
greatest variance of survival rate diﬀerence at the levels of 15
LNs (stage I), 25 LNs (stage II), and 30 LNs (stage III).6 Gastroenterology Research and Practice
4. Discussion
It is generally accepted that a higher survival rate beneﬁts
from the standardized pattern of lymph node dissection
[13–15]. Many studies have shown that the number of
dissected LNs is closely related to the postoperative patho-
logic staging and prognostic assessment. A suﬃcient number
of lymph nodes dissected could improve staging reliability
and prognostic assessment accurately [16, 17]. Sun et al.
[18] reviewed 2159 patients with gastric cancer who had
undergone gastrectomy with curative intent. They found
that closed linear correlations were observed between the
number of retrieved LNs and the number of metastatic
nodes. Meanwhile, on account existence of lymph node
micrometastases [19–21], the result of exploration for
lymph node metastases by routine H&E staining may not
exactly reﬂect the prognosis. As a result, better long-term
survival has been observed with higher total LNs, showing
the contribution of suﬃcient lymphadenectomy toward
reducing the positive and micrometastasic lymph nodes.
According to our data, the median number of total LNs
examined was 23 (mean 23.1 ± 8.6) per patient. There was
a signiﬁcant correlation between the number of metastatic
lymph nodes and retrieved nodes according to the Pearson’s
correlation test (P<0.0 5 ) .W et h u sc o n c l u d et h a tap r o p e r
increment of the dissected LN count contributes to the
reduction of the number of residual tumor cells. On the
other hand, a research result from Italy has pointed out that
the number of LNs dissected emerged as one of the most
important prognostic indicators [22]. In our present study,
the number of dissected LNs was modeled as a common
variable. In the multivariate survival analysis, the number
of dissected LNs, as well as depth of invasion and lymph
node involvement, was one of the independent predictors of
survival.Inaddition,thenumberofdissectedLNsisthemost
important predictor of survival that can be inﬂuenced by
the surgeons, especially for the patients without preoperative
chemotherapy and underwent a curative resection (R0).
Furthermore, a preoperative diﬀerential diagnosis between
mucosal and deeper gastric cancer is diﬃcult, and it is hard
to localize or predict the extension of lymph node metastasis
by the current available techniques. And a complete surgical
resection with an en bloc LN dissection is still an important
p r o c e d u r et oi m p r o v es u r v i v a lf o rg a s t r i cc a n c e r .T h e r e f o r e ,
the authors propose that an adequacy number of dissected
LNs are not only a demand for accurate staging, but
also a surrogate marker related to the quality of gastric
cancer surgery; it reﬂects the extent of LN dissection and
signiﬁcance for improving survival in patients with gastric
cancer.
In 2003, Le Voyer et al. [23] published a secondary
analysis of intergroup trial INT-0089. They emphasized the
importance of the number of LNs examined determining
prognosis on colon cancer. Additionally, they believed that
staging accuracy and survival were improved with increasing
nodal examination and analysis. However, there was no
international multicentre prospective randomized study on
the impact of the removed nodes on outcome in patients
with gastric cancer. Smith et al. [9] reviewed T1-3N0-1
gastric cancer with curative intent. They found that in every
stage subgroup, overall survival was highly dependent on
the number of LNs examined. The higher the number of
LNs examined, the better the resulting postgastrectomy
survival would be. Schwarz and Smith [10] believed that
the results speak for a therapeutic beneﬁt as a result of
extended lymph node dissection, even in patients with more
advanced (stage III and IV) yet resectable gastric cancer.
The results in our present study also showed that, with
comparable T category, the overall survival was signiﬁcantly
diﬀerent (P<0.05), and always in favor of the higher
LN counts. From the investigation of the linear projection
model, a statistical signiﬁcant survival improvement based
on increasing LNs counts was obvious for stage II and stage
III subgroups analyzed. So, if patients were estimated with
more advanced gastric cancer preoperation, more dissected
LNs should be achieved during the operation. Dissection
of much more lymph nodes with the increased stage may
improve long-term survival of gastric cancer patients.
The NCCN Clinical Practice Guidelines in Oncology-
Gastric Cancer Guideline requires surgeons to make a preop-
erative staging via endoscopic ultrasonography, abdominal
ultrasonography, computed tomography (CT), and so on
preoperation, in order to choose diﬀerent therapies for
patients with diﬀerent stages. In this paper, we expected the
surgeons to estimate the TNM stage before or during the
operation and choose the diﬀerent scopes of LN dissection
to obtain suﬃcient number of dissected LNs. However, it
is yet unclear whether suﬃcient lymph node dissection is
needed for staging or better prognosis. How many nodes
should be removed after the radical distal gastrectomy for
diﬀerent stages which lead a better survival? Lee et al. [24]
showed that patients with gastric cancer should undergo
adequate lymphadenectomy to permit examination of ≥15
LNs, whichwouldallow accurateidentiﬁcation of prognostic
variables. Removal of ≥15 LNs is associated with higher
survival rate for patients with this disease. Another study
from Marubini et al. [25], however, suggested that removal
o f1 5L N si ss t i l li n s u ﬃcient, an extended lymphadenectomy
may always be preferable, and the risk of long-term death
tends to decrease when the number of resected lymph nodes
increases to about 25. Based on the results of the cut-point
analysis, we consider that the number of dissected LNs could
help us to evaluate the patients’ prognosis, and removal
of 15 LNs for stage I, 25 LNs for stage II, and 30 LNs
f o rs t a g eI I Ii sr e c o m m e n d e df o ra na d e q u a t eL Nr e s e c t i o n
during the curative distal gastrectomy for the patients with
gastric cancer, who achieve the best long-term survival
outcomes.
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